Immediate Impact
2 from Science/Nature 62 standout
Citing Papers
A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells
2024 Standout
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
2024 Standout
Works of Mihaela Druta being referenced
Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS).
2022
Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043).
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Mihaela Druta | 237 | 240 | 70 | 42 | 413 | |
| Michael J. Nathenson | 221 | 281 | 50 | 29 | 428 | |
| Evan Rosenbaum | 242 | 178 | 37 | 33 | 391 | |
| Elisabetta Setola | 189 | 310 | 41 | 25 | 457 | |
| David S. Moura | 233 | 262 | 52 | 48 | 488 | |
| V. Tison | 125 | 167 | 54 | 26 | 471 | |
| José G. Mantilla | 142 | 236 | 36 | 33 | 463 | |
| James B. Hayden | 177 | 263 | 58 | 30 | 474 | |
| Timuçin Çil | 106 | 113 | 45 | 53 | 448 | |
| C Rimbaut | 74 | 179 | 32 | 25 | 380 | |
| Bhuvana A. Setty | 105 | 115 | 43 | 45 | 470 |
All Works
Loading papers...